Krystal Biotech (KRYS) News Today

Krystal Biotech (NASDAQ:KRYS) Reaches New 12-Month High at $218.55

Sei Investments Co. lifted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 128.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 33,752 shares of the company's stock after buying an additional 18,968 shares dur

Scout Investments Inc. bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 50,977 shares of the company's stock, valued at approximately $8,976,000. Scout Inv

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Stock analysts at William Blair increased their Q2 2024 earnings per share (EPS) estimates for shares of Krystal Biotech in a research report issued to clients and investors on Tuesday, July 16th. William Blair analyst T. Lugo now forecasts that

SG Americas Securities LLC cut its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 62.9% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 7,007 shares of the company's stock after selling 11,858 shares during the period. SG Americas

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) saw a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 3,510,000 shares, a growth of 21.0% from the June 15th total of 2,900,000 shares. Based on an average daily volume of 384,100 shares, the short-interest ratio is currently 9.1 days.

Krystal Biotech (NASDAQ:KRYS) Sets New 1-Year High at $205.25

BNP Paribas Financial Markets reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 57.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,778 shares of the company's stock after selli

TimesSquare Capital Management LLC decreased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 61.2% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 97,161 shares of the company's stock

Janney Montgomery Scott LLC purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 17,843 shares of the company's stock, valued at approximately $3,

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have earned an average recommendation of "Buy" from the nine ratings firms that are currently covering the company, Marketbeat reports. Nine analysts have rated the stock with a buy recommendation. The average 1-year price target amon

Jennison Associates LLC lessened its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 7.4% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 670,735 shares of the company's stock after selling 53,609 shares during t

Krystal Biotech (NASDAQ:KRYS) Reaches New 12-Month High at $192.49

Allspring Global Investments Holdings LLC raised its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 167.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 158,425 shares of the company's

Vanguard Group Inc. raised its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 1.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,435,774 shares of the company's stock after acquiring an additiona

Goldman Sachs Group Inc. boosted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 23.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 228,053 shares of the company's stock after purchasing an additional 43,709 shares during the

Krystal Biotech (NASDAQ:KRYS) Reaches New 52-Week High at $189.98

Braidwell LP boosted its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 153.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 196,200 shares of the company's stock after buying an additional 118,703 sh

Eventide Asset Management LLC acquired a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 136,485 shares of the company's sto

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the transaction, the insider now owns 1,525,882 shares of the company's stock, valued at approximately $268,189,020.32. The sale was disclosed in a document filed with the SEC, which is available at this link.

Superstring Capital Management LP bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 16,086 shares of the company's stock, valued at approximately $1,996,000.

Krystal Biotech (NASDAQ:KRYS) Shares Gap Up to $164.42

TD Asset Management Inc increased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 82.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 40,962 shares of the company's stock after purchas

Affinity Asset Advisors LLC lowered its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 56.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 25,000 shares of the company's stock after selling 32,500 shares during the period. Affin

Decheng Capital LLC bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 65,772 shares of the company's stock, valued at a

Dimensional Fund Advisors LP increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 5.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 550,806 shares of the company's stock after buy

Charles Schwab Investment Management Inc. increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 185,038 shares of the company's

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) Director Julian S. Gangolli sold 20,000 shares of the business's stock in a transaction on Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

BNP Paribas Financial Markets grew its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 34.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,072 shares of the company's stock after purchasing

Fiera Capital Corp purchased a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 15,900 shares of the company's stock, valued at approximately $1,973,000. Fiera Capital

Nicholas Investment Partners LP lowered its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 86.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,073 shares of the

Russell Investments Group Ltd. reduced its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 34.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,479 shares of the company's stock after selling 13,21

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2024 earnings estimates for shares of Krystal Biotech in a report issued on Tuesday, May 7th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn $4.00 per shar

Victory Capital Management Inc. reduced its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 17.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 172,879 shares of the company's stock after selling 36,608 share

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Investment analysts at William Blair boosted their Q3 2024 EPS estimates for shares of Krystal Biotech in a research note issued to investors on Monday, May 6th. William Blair analyst T. Lugo now expects that the company will earn $0.63 per shar

New York State Common Retirement Fund lessened its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 32.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,993 shares of the company's stock after sellin

TimesSquare Capital Management LLC grew its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 103.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,470 shares of the company's st

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Analysts at HC Wainwright upped their Q2 2024 EPS estimates for Krystal Biotech in a report issued on Monday, May 6th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $0.37 for the quarter, up fr

Krystal Biotech (NASDAQ:KRYS - Get Free Report) posted its earnings results on Monday. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.17). The company had revenue of $45.25 million during the quarter, compared to analysts' expectations of $47.37 million. Krystal Biotech's revenue for the quarter was up 452400.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.76) EPS.